When Empty Threats Work: “Price Negotiation” In White House Budget Spooks Wall Street
This article was originally published in RPM Report
Executive Summary
Investors remain hyper-sensitive to any threat to pricing flexibility for biotech products. The latest over-reaction – to a renewed call for Medicare “price negotiation” – meant missing some of the more meaningful messages coming from Washington about support for innovation.